Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
4.160
-0.100 (-2.35%)
At close: Dec 20, 2024, 4:00 PM
4.200
+0.040 (0.96%)
After-hours: Dec 20, 2024, 6:56 PM EST
Relay Therapeutics Employees
Relay Therapeutics had 323 employees as of December 31, 2023. The number of employees decreased by 4 or -1.22% compared to the previous year.
Employees
323
Change (1Y)
-4
Growth (1Y)
-1.22%
Revenue / Employee
$30,978
Profits / Employee
-$1,068,728
Market Cap
696.31M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 323 | -4 | -1.22% |
Dec 31, 2022 | 327 | 82 | 33.47% |
Dec 31, 2021 | 245 | 86 | 54.09% |
Dec 31, 2020 | 159 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Avanos Medical | 3,771 |
Bioventus | 970 |
Axogen | 428 |
Evolus | 273 |
Ironwood Pharmaceuticals | 267 |
IRADIMED CORPORATION | 148 |
Kura Oncology | 142 |
Keros Therapeutics | 136 |
RLAY News
- 10 days ago - Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewsWire
- 12 days ago - Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 18 days ago - Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire
- 18 days ago - Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewsWire
- 6 weeks ago - Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - GlobeNewsWire
- 3 months ago - Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion - Seeking Alpha
- 3 months ago - Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations - Seeking Alpha